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Abstract
Hypertension is the leading risk factor for cardiovascular disease and one of the major health concerns worldwide. Genetic factors
impact both the risk for hypertension and the therapeutic effect of antihypertensive drugs. Sex- and age-speciﬁc variances in the
prevalence of hypertension are partly induced by estrogen. We investigated 6 single nucleotide polymorphisms in genes encoding
enzymes involved in estrogen metabolism in relation to sex- and age-speciﬁc differences in the systolic and diastolic blood pressure
(SBP and DBP) outcome under the treatment of diuretics, calcium-channel blockers (CCBs), angiotensin-converting-enzyme
inhibitors, and angiotensin-receptor blockers (ARBs).
We included 5064 subjects (age: 40–82) from the population-based CoLaus cohort. Participants were genotyped for the catechol-
O-methyltransferase gene (COMT) variants rs4680, rs737865, and rs165599; the uridine-diphospho-glucuronosyltransferase 1A
gene family (UGT1A) variants rs2070959 and rs887829; and the aromatase gene (CYP19A1) variant rs10046. Binomial and linear
regression analyses were performed correcting for age, sex, body mass index, smoking, diabetes, and antihypertensive therapy to
test whether the variants in focus are signiﬁcantly associated with BP.
All investigated COMT variants were strongly associated with the effect of diuretics, CCBs, and ARBs on SBP or DBP (P< .05),
showing an additive effect when occurring in combination. After Bonferroni correction the polymorphism rs4680 (Val158Met) inCOMT
was signiﬁcantly associated with lower SBP in participants treated with CCBs (P= .009) with an especially strong impact in elderly
individuals (age ≥ 70) alone (D=14.08 mm Hg, P= .0005).
These results underline the important role of estrogens and catecholamines in hypertension and the importance of genotype
dependent, age-related adjustments of calcium-channel blocker treatment.
Abbreviations: ACEI = angiotensin-converting-enzyme inhibitors, ARBs = angiotensin-receptor blockers, ATC = Anatomical
Therapeutic Chemical, Beta = standardized beta coefﬁcient, BMI = body mass index, BP = blood pressure, CCBs = calcium-
channel blockers, COMT = catechol-O-methyl transferase, CVD = cardiovascular disease, CYP19A1 = aromatase, DBP = diastolic
blood pressure, HWE =Hardy–Weinberg equilibrium, Padj = adjusted P value obtained by using logistic regression analyses, Punadj =
unadjusted P value, SBP = systolic blood pressure, SNP = single nucleotide polymorphism, UGT1A = uridine-diphospho-
glucuronosyltransferase 1A, UTR = untranslated region, D = difference of mean blood pressure levels between wildtype carriers and
minor allele carriers of speciﬁc genetic variants under comparison (reference value = blood pressure level of wildtype carriers).
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Currently, hypertension affects nearly one-third of the adults
worldwide.[1] It is a major risk factor for cardiovascular diseases
(CVDs), which are major causes of morbidity and mortality.[2–6]
The number of adults with hypertension in 2025 has been
predicted to increase by about 60% to a total of 1.56 billion.[7]
Hypertension is especially prevalent in the elderly population.[8,9]
Furthermore, the risk for clinical complications such as coronary
artery disease, congestive heart disease, stroke, chronic kidney
insufﬁciency, and dementia is also higher in this subgroup of
population.[8] The pathogenesis of high arterial blood pressure
(BP) is known to be inﬂuenced by both environmental and genetic
factors. It is estimated that genetic factors are responsible for
30% to 50% of BP differences seen among individuals.[3]
Various treatment strategies are available to help controlling BP
and reducing the risk for associated clinical complications.[10]
Especially in elderly patients, age 70 years and older, hypertension
management represents a dilemma.[8,9] Treatment with antihy-
pertensives in this patient group appears to be not as efﬁcient with
regard to BP adjustment compared with younger patients, as
elderlypatients takingantihypertensivemedicationshave shown to
be atmuch higher risk for ischemic events and poor oxygenation in
brain, heart, or kidney than younger patients.[8]
First-line drugs against hypertension include diuretics, calci-
um-channel blockers (CCBs), angiotensin-converting-enzyme
inhibitors (ACEIs), and angiotensin-receptor blockers (ARBs).[11]
However, the therapeutic effect of these medications varies
among individuals, which is partly induced by genetic
variants.[10,12] Furthermore, a sex dimorphism has been shown
to exist for BP regulation as demonstrated in several population-
based studies. This effect has been attributed to different estrogen
levels in men and women and associated differences in the
estrogen-dependent expression of proteins involved in BP
regulation.[3,4,13–16] Thus, variances in the activity of proteins
involved in estrogen metabolism, as caused by, for example,
genetic polymorphisms, may inﬂuence the risk for hyperten-
sion.[3]
The enzyme catechol-O-methyltransferase (COMT) catalyzes
the transformation of estrogen and other catechol substrates into
methylated inactive metabolites.[17] The polymorphism rs4680
(Val158Met) in COMT drives major individual differences in the
enzymatic activity of COMT.[18] Homozygous Met (A) allele
carriers showed signiﬁcantly decreased COMT activity, higher
BP, and hypertension prevalence in Japanesemen, comparedwith
Met/Val or Val/Val carriers.[19–21] The intronic single nucleotide
polymorphism (SNP) rs737865 and the polymorphism rs165599
near the 30 untranslated region (UTR) induce an additional
variation in COMT activity.[18,22]
The enzyme family uridine-diphospho-glucuronosyltransfer-
ase 1A (UGT1A) facilitates estrogen excretion by preventing
enhanced tissue exposure to the hormone, thus, weakening
estrogen receptor-dependent signaling.[23] The polymorphisms
rs2070959 (Thr181Ala) and rs887829 are located in the genes
UGT1A6 and UGT1A1, respectively. Together with the variant
rs1105879 (Arg184Ser, UGT1A6), rs2070959 causes 30% to
50% lower activity of UGT1A6.[24]
The aromatase CYP19A1 catalyzes the key step of estrogen
synthesis from androgens and, thus, impacts the serum estrogen-
androgen balance.[3,4] The SNP rs10046 located in the 30 UTR of
CYP19A1 has been associated with higher and lower serum
estradiol levels in different studies.[3,25] Several publications have
discussed the role of CYP19A1 polymorphisms as risk markers
for general or sex-dependent susceptibility to hypertension.[13,26]2While several studies have addressed the impact of estrogen
levels and a modulated estrogen metabolism on BP levels, no
previous study has systematically investigated the impact of
genetic variants in key genes involved in estrogen transformation
on the therapeutic effect of speciﬁc types of antihypertensive
drugs.
To close this gap of knowledge we investigated the association
of 6 genetic variants within the estrogen transforming genes
COMT, UGT1A, and CYP19A1 with the therapeutic effect of
antihypertensive drugs (i.e., diuretics, CCBs, ACEIs, and ARBs)
in a population-based cohort study CoLaus, including 5064
subjects of Swiss origin, 1337 of them treated with different types
of antihypertensive drugs. Importantly, we scrutinized whether
genetically induced sex- or age-speciﬁc effects are abundant with
regard to treatment outcome with the mentioned therapeutics.
2. Materials and methods
2.1. Study design and subjects
We included individuals from the population-based CoLaus
cohort in our analyses. The primary aim of the CoLaus study was
to evaluate the prevalence and determinants of CVD in the
Caucasian population living in Lausanne, Switzerland. The
sampling methodology of the CoLaus study has been previously
described.[27] In brief, the CoLaus study (2003–2006) enrolled
6733 participants at baseline, of whom 5064 participants were
re-contacted for a follow-up visit (2009–2012). All participants
attended the outpatient clinic at the University Hospital of
Lausanne after an overnight fast with a minimum fasting period
of 8h. The visit included a personal interview and a physical
examination conducted by trained ﬁeld interviewers. At baseline,
the age of participants ranged between 35 and 75 years. The
average follow-up period was 5.4 years with an interquartile
range of 5.3 to 5.6 years. The study was approved by the local
Institutional Ethics Committee of the University of Lausanne.
Written informed consent was obtained from all participants.
In the frame of our study, we included clinical and genotyping
data of individuals collected during the follow-up visit. Systolic
blood pressure (SBP) and diastolic blood pressure (DBP) were
measured 3 times on the left arm in a sitting position after an
initial resting period of at least 10 min. BP measurements were
performed using an Omron HEM-907 automated oscillometric
sphygmomanometer. The BP measurements considered in the
present study are average values of the 2 last measurements.
Based on smoking habits, participants were categorized into
current smokers, never smokers, and former smokers. Diabetes
was deﬁned as showing fasting plasma glucose≥7mmol/L and/or
using antidiabetic medications or insulin. Body weight and height
were measured without shoes in light indoor clothes. Body mass
index (BMI) was calculated as weight (kg) divided by the height
squared (m2). Menopause status was deﬁned as the absence of
menstruation. Information on perimenopause was not collected.
Antihypertensive medications were coded using the Anatomi-
cal Therapeutic Chemical (ATC) classiﬁcation system. Treatment
combinations were split into the medication classes they
contained. For instance, the ATC code C09DA01 representing
the combination of Losartan and diuretics was split into the
antihypertensive medication groups of “ARBs” and “diuretics.”
2.2. Genotyping
In the CoLaus study, nuclear DNA was extracted from whole
blood. Genotyping was conducted using the Affymetrix 500K
Figure 1. Flow chart illustrating study design and objectives tested. Initially,
statistical analyses were performed in the whole population testing for
differences in BP levels in relation to genetic variants in genes involved in
estrogen metabolism. In addition, the inﬂuence of these SNPs on BP under the
treatment of antihypertensive drugs was tested. Both unadjusted and adjusted
analyses were performed. Adjusted analyses were conducted correcting
for age, sex, BMI (kg/m2), smoking habits, diabetes, antihypertensive
polymedication, and menopausal state (included as covariate in analyses
investigating speciﬁcally pre- and postmenopausal women). In multiple
comparisons, statistically signiﬁcant values were evaluated based on
Bonferroni corrected P values. Statistical outcomes reaching Bonferroni
corrected P value thresholds (P< .01) were further investigated in sex- and
age-related interaction and stratiﬁcation analyses (age cutoff: 70 years). ACEIs
= angiotensin-converting-enzyme inhibitors, ARBs = angiotensin-receptor
blockers, BMI = body mass index, CCBs = calcium-channel blockers, LD =
linkage disequilibrium, N = number of subjects, SNP = single nucleotide
polymorphism.
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investigated. The SNPs rs737865 (A/G), rs4680 (A/G,Met158Val),
and rs165599 (A/G) are locatedwithin thepromoter, in exon4and
within the 30 UTR of COMT, respectively. The genetic variants
rs2070959 (A/G, Thr181Ala) and rs887829 (C/T) are located in
exon 1 ofUGT1A6 and in the core promoter region ofUGT1A1,
respectively.[28] The genetic variant rs10046 (A/G) is located close
to the 30 UTR of CYP19A1. All variants were imputed based on
linkage behavior obtaining values between 0 and 2. The applied
cut-off values for inclusion into the study were 0.2, 0.8, 1.2, and
1.8, and rounded to the values 0 (wildtype), 1 (heterozygous
mutated), and 2 (homozygous mutated), respectively. Hardy–-
Weinberg equilibrium (HWE) was tested using the package
“Hardy–Weinberg” inR,which applies a Fisher exact test on allele
frequencies.Noneof the SNPsdeviated fromHWE.The estimation
of linkage disequilibrium between SNPs was performed using
Haploview 4.1 software.
2.3. Generation of a combined genetic COMT score
Based on the effect on BP under treatment with CCB, a combined
geneticCOMTscorewasdeﬁned, taking the3 investigatedCOMT
variants into consideration. For each allele lowering the BP under
CCB treatment 1 point was given. Thus, based on the number of
alleles, individuals were reaching a COMT score between 0 and 6.
2.4. Statistical analysis
The unpaired Student t test (2-tailed) or the Mann–Whitney U
test was applied to test for differences of continuous variables
between 2 subgroups in unadjusted analyses.
A general linear model (univariate) was applied to investigate
the additive impact of risk alleles on BP levels (mmHg). Sitting BP
levels (mmHg) and genotypes were chosen as dependent outcome
parameters in linear and logistic regression analyses, respectively.
Binomial logistic and multiple-linear regression analyses were
applied to correct for important covariates, such as age, sex
(female=0, male=1), BMI (kg/m2), current tobacco smoking,
diabetes, menopause state, as well as the intake of more than
one type of BP-lowering drug. Menopausal state was included
as covariate for analyses investigating the group of women
comprising both pre- and postmenopausal subjects. To assess
whether sex or age exerted an impact on the association between
genotype and the therapeutic effect of antihypertensives, different
statistical models were constructed to test for potential
interactions between genotypes, sex and age with sitting SBP
and DBP levels as outcome variable. Speciﬁcally, the following
interaction terms were included in the model: genotype∗sex,
genotype∗age and genotype∗age∗sex.
A P value< .05 was considered signiﬁcant in both unadjusted
and adjusted analyses. In multiple comparisons, statistically
signiﬁcant values were evaluated based on Bonferroni corrected
P value thresholds to control for type I error. Differences in SBP
or DBP over 10 or 5 mmHgwere evaluated as clinically relevant.
The statistical analyses were performed using SPSS software
(Version 23.0.0). The ﬂow chart representing the steps of the
analysis approach is shown in Fig. 1.
3. Results
3.1. Outcome of clinical characteristics in the investigated
cohort
As shown in Table 1, sexes were equally represented in the
CoLaus cohort (men=2357, women=2707). In the whole3cohort, ARBs (men/women=353/302) were the most often
prescribed antihypertensive drug group, followed by diuretics
(men/women=262/241), ACEIs (men/women=210/149), and
CCBs (men/women=132/102) (Table 1). Men had signiﬁcantly
higher sitting SBP and DBP levels than women in unadjusted
analyses (P< .001) (Table 1). Furthermore, signiﬁcant differences
were detected between men and women with regard to age,
smoking habits, diabetes, BMI (kg/m2), whether or not taking
antihypertensives in mono- or combination therapy (P< .05)
(Table 1). These parameters were used as covariates in
subsequently performed adjusted analyses investigating the
association of genetic variants with sitting SBP and DBP levels.
3.2. Genotyping results
All 6genetic variants investigated in thepresent studywere inHWE
(Table 2). Two SNPs rs2070959 (UGT1A6) and rs887829
(UGT1A1) were identiﬁed to be in strong linkage disequilibrium
0 2
Table 1
Clinical characteristics of the subjects from the population-based CoLaus cohort.
Clinical characteristics, N All (5064) Women (2707) Men (2357) P
Age 57.764±0.148 (5064) 58.234±0.202 (2707) 57.225±0.217 (2357) .001
Smoker (%) 1089/5007 (21.7%) 549/2668 (20.6%) 540/2339 (23.1%) .033
Diabetes (%) 539/5044 (10.7%) 168/2697 (6.2%) 371/2347 (15.8%) .000
BMI, kg/m2 26.195±0.065 (4999) 25.521±0.096 (2673) 26.971±0.084 (2326) .000
Sitting systolic BP (mm Hg) 126.128±0.252 (5048) 122.21±0.353 (2696) 130.623±0.337 (2352) .000
Sitting diastolic BP (mm Hg) 78.059±0.152 (5048) 76.403±0.206 (2696) 79.958±0.220 (2352) .000
AHT (%) 1337/5064 (26.4%) 640/2707 (23.6%) 697/2357 (29.6%) .000
Co-AHT (%) 448/5064 (8.8%) 199/2707 (7.4%) 249/2357 (10.6%) .000
Diuretics (%) 503/5064 (9.9%) 241/2707 (8.9%) 262/2357 (11.1%) .010
Calcium-channel blockers (%) 234/5064 (4.6%) 102/2707 (3.8%) 132/2357 (5.6%) .002
Angiotensin-converting-enzyme inhibitors (%) 359/5064 (7.1%) 149/2707 (5.5%) 210/2357 (8.9%) .000
Angiotensin-receptor blockers (%) 655/5064 (12.9%) 302/2707 (11.2%) 353/2357 (15.0%) .000
The results are shown as mean± standard error of mean. P values representing the differences of tobacco smoking, diabetes, whether or not under (distinct types of) antihypertensive treatment and whether or not
taking more than one type of BP-lowering medications between men and women were obtained using chi-squared tests (2-sided); Unadjusted P values testing for differences of age, BMI, systolic and diastolic BP
between men and women were obtained using the unpaired Student t test (2-sided). P< .05 was considered as signiﬁcant and is shown in bold.
AHT= taking at least one type of antihypertensive drug, BMI = body mass index, BP = blood pressure, Co-AHT= taking more than one type of antihypertensive drug, N= the number of subjects.
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combining these 2 variants was considered in subsequent analyses;
38.6%of subjects carried thewildtype formof this haplotypewhile
55.2% of subjects carried the haplotype UGT1AGT in heterozy-
gous and homozygous form. These 2 groups of subjects were
compared in subsequent analyses; 6.2% of subjects were carrying
other haplotypes composed of only 1 genetic variant.3.3. A COMT variant is signiﬁcantly associated with lower
BP in patients taking CCB
Initially, we investigated to what extent the 6 SNPs in focus are
associated with SBP and DBP. As shown in Table 3 (ﬁrst column),
none of the SNPs showed a relevant strong effect on BP before
subgrouping into different treatment groups (P> .05).
After dividing participants into subgroups according to
antihypertensive treatment, the COMT SNP rs4680 was
associated with lower BP levels in patients taking CCBs (SBP:
Punadj= .009, Padj= .008) or ARBs (DBP: Punadj= .037) (Table 3).
The other 2 COMT variants rs737865 and rs165599 were
associated with higher SBP levels in participants treated with
CCBs (rs737865: Punadj= .041, Padj= .032; rs165599: Punadj
= .019, Padj= .035) (Table 3). Individuals treated with diuretics
showed lower SBP levels compared with wildtype carriers when
carrying the genetic variant rs737865 (Punadj= .023, Padj= .039)
(Table 3). The haplotype UGT1AGT and rs10046 in CYP19A1
was not associated with a modulated therapeutic effect of
antihypertensives (P> .05) (Table 3). Furthermore, none of the
investigated genetic variants exhibited a signiﬁcant effect inTable 2
Genotype frequencies of SNPs investigated in the population-based
Allele (forward) Genotype frequency
SNP Gene Major Minor Wild type Heterozygous Homozy
rs4680 COMT A (Met) G (Val) 1013 2078 997
rs737865 COMT A G 1830 1692 367
rs165599 COMT A G 1914 1607 318
rs2070959 UGT1A6 A (Thr) G (Ala) 1673 1866 514
rs887829 UGT1A1 C T 1707 1877 525
rs10046 CYP19A1 A G 1104 2026 977
SNP = single nucleotide polymorphism.
4individuals taking ACEIs (P> .05) (Table 3). After Bonferroni
correction (P< .01 [0.05/5]), the association of COMT SNP
rs4680 with SBP in individuals treated with CCBs was remained
signiﬁcant (Table 3).3.4. A COMT variant is signiﬁcantly associated with lower
systolic BP especially in elderly individuals taking CCB
As illustrated in Table 4, multiple linear regression analyses
revealed that the association of rs4680 (COMT) with SBP in
participants taking CCBs (beta=0.194, P= .007) appeared to
be especially inﬂuenced by age (beta=0.167, P= .024) and sex
(beta=0.148, P= .042). By contrast, no signiﬁcant association
was detected between rs4680 and DBP in participants treated
with CCBs (P> .05) (Table 4).
Therefore, we investigated in the next step to what extent age
or sex inﬂuence the association between rs4680 and the
therapeutic effect of CCBs. As shown in Table 5, a signiﬁcant
interaction between rs4680 and age was observed in patients
treated with CCBs (SBP: P= .004, DBP: P= .006). Interestingly,
the observed signiﬁcant differences in BP were limited to elderly
individuals ≥70 years of age. In this subgroup, rs4680 carriers
treated with CCBs showed signiﬁcantly lower SBP levels
compared with wildtype carriers (D=14.08 mm Hg, Punadj
= .0005, Padj= .0019) (Table 6, Fig. 2A). Although not signiﬁ-
cant, DBP levels tended to be lower in elderly rs4680 carriers
taking CCBs (D=4.97 mm Hg) (Table 6, Fig. 2C). In line with
this observation, we detected in this subject group stepwise
increasing differences in SBP levels in relation to the number ofCoLaus cohort.
gous Minor allele proportion (%) n P (Hardy–Weinberg equilibrium)
49.80 4088 .287
31.19 3889 .397
29.21 3839 .452
35.70 4053 .858
35.62 4109 .799
48.45 4107 .425
Table 4
Multiple-linear regression analyses investigating the association of COMT genetic variant rs4680 with SBP and DBP in patients treated
with CCBs.
Multiple-linear regression models
Outcome: SBP Outcome: DBP
Drug† (SNP) Predictors Beta P Predictors Beta P
CCBs (Rs4680) SNP 0.194 .007∗∗ SNP 0.044 .519
Age 0.167 .024
∗
Age 0.335 .000∗∗
Sex (F=0) 0.148 .042
∗
Sex (F=0) 0.029 .675
BMI 0.039 .611 BMI 0.132 .071
Smoking 0.102 .159 Smoking 0.180 .010∗
Diabetes 0.061 .413 Diabetes 0.133 .063
Co-AHT 0.053 .480 Co-AHT 0.022 .757
Models were adjusted for the speciﬁc genetic variant (whether or not carrying the minor allele), age, sex (F=0), BMI (kg/m2), smoking habits, diabetes, and antihypertensive polymedication. P values<.05 were
considered as signiﬁcant and set in bold.
Beta= standardized beta coefﬁcient, BMI = body mass index, CCBs= calcium-channel blockers, Co-AHT= treatment with more than one type of antihypertensive medication, DBP=diastolic BP, F = female,
SBP= systolic BP.
† Adjusted multiple-linear regression models were applied on Bonferroni corrected signiﬁcant associations listed in Table 3.
∗
P< .05.
∗∗
P< .01.
Table 3
Association of genetic variants inCOMT,UGT1A, andCYP19A1 genes with blood pressure in the whole population and in patients treated
with distinct types of antihypertensive medications.
All individuals Diuretics CCBs ACEIs ARBs
SNP BP D† Punadj‡ Padjx D† Punadj‡ Padjx D† Punadj‡ Padjx D† Punadj‡ Padjx D† Punadj‡ Padjx
rs4680 SBP 0.87 ns ns 0.63 ns ns 6.53 .009∗∗ .008∗∗ 1.28 ns ns 1.16 .525 .924
DBP 0.14 ns ns 0.92 ns ns 1.07 .560 .509 0.57 ns ns 2.37 .037∗ .138
N 1009/3066 104/314 55/137 71/233 134/407
rs737865 SBP 0.87 ns ns 4.09 .023∗ .039∗ 4.76 .041∗ .032∗ 1.43 ns ns 2.59 ns ns
DBP 0.09 ns ns 1.15 .485 .574 2.77 .094 .132 1.02 ns ns 0.21 ns ns
N 1824/2052 193/213 83/102 134/155 251/279
rs165599 SBP 0.07 ns ns 1.06 ns ns 5.76 .019∗ .035∗ 0.48 ns ns 0.21 ns ns
DBP 0.40 ns ns 1.36 ns ns 2.45 .157 .222 1.34 ns ns 1.11 ns ns
N 1907/1920 189/195 82/93 147/140 258/248
UGT1AGT SBP 0.21 ns ns 0.04 ns ns 4.32 ns ns 0.14 ns ns 0.54 ns ns
DBP 0.19 ns ns 0.25 ns ns 2.13 ns ns 0.35 ns ns 0.59 ns ns
N 1554/2229 167/223 78/100 114/160 212/292
rs10046 SBP 0.19 ns ns 0.70 ns ns 2.53 ns ns 2.28 ns ns 0.24 ns ns
DBP 0.10 ns ns 1.17 ns ns 0.69 ns ns 1.56 ns ns 0.49 ns ns
N 1103/2991 106/316 48/148 80/225 156/390
Signiﬁcant associations after Bonferroni correction with P< .01 (0.05/5) are shown in bold.
ACEIs= angiotensin-converting enzyme inhibitors, ARBs= angiotensin-receptor blockers, BP=blood pressure, CCBs= calcium-channel blockers, DBP=diastolic BP, N=number of subjects (wildtype/variant
carriers), ns = not signiﬁcant, SBP= systolic BP.
† Difference of SBP or DBP mean values between wildtype and variant carriers (reference value: wildtype) (mm Hg).
‡ Unadjusted P values obtained when testing for differences of SBP or DBP between wildtype and variant carriers using the unpaired Student t test (2-sided).
x Adjusted P values obtained using binomial logistic regression analyses correcting for age, sex, body mass index (kg/m2), smoking, diabetes, antihypertensive therapies.
∗
P< .05.
∗∗
P< .01.
Table 5
Blood pressure lowering effects of CCBs in relation to COMT rs4680 genotypes (AA vs. AG+GG) and interactions with age and sex.
P Observed power
Variables (N) Genotype∗sex Genotype∗age Genotype∗age∗sex Genotype∗sex Genotype∗age Genotype∗age∗sex
SBP (192) .048
∗
.004
∗∗
.077 0.589 0.858 0.514
DBP (192) .444 .006
∗∗
.440 0.188 0.832 0.190
P value and observed power were obtained using general linear model to assess whether and to how much degree sex or age exerted a signiﬁcant impact on the association between the variant rs4680 genotype
and the response to CCBs. Models were tested for interactions between genotypes, sex, and age with respect to SBP and DBP levels. Speciﬁcally, the following interaction terms were included in the model:
genotype∗sex, genotype∗age, and genotype∗age∗sex. P values <.05 were considered as signiﬁcant. Signiﬁcant associations with observed power >0.8 were shown in bold.
CCBs= calcium-channel blockers, DBP=diastolic blood pressure, N=number of subjects, SBP= systolic blood pressure.
∗
P< .05.
∗∗
P< .01.
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Table 6
Subgroup analyses to investigate the effect of age or sex on the associations between the COMT SNP rs4680 and systolic or diastolic
blood pressure in individuals treated with CCBs.
SBP DBP
Stratiﬁcation Subgroups Genotype N SBP, mm Hg D†, mm Hg Punadj‡ Padjx DBP, mm Hg D†, mm Hg Punadj‡ Padjx
Age <70 AA 35 135.03 79.53
AG+GG 80 132.86 2.17 .491 .588 81.38 1.85 .415 .553
≥70 AA 20 146.52 77.83
AG+GG 57 132.44 14.08 .0005∗∗ .0019∗∗ 72.86 4.97 .079 .216
Sex Male AA 33 140.08 78.85
AG+GG 81 134.56 5.52 .081 .052 77.48 1.37 .530 .595
Female AA 22 137.91 79.00
AG+GG 56 129.96 7.95 .051 .074 78.36 0.64 .843 .785
P values< .05 were considered signiﬁcant and shown in bold.
BP=blood pressure, CCBs= calcium-channel blockers, DBP=diastolic BP, N=number of subjects (wildtype/variant carriers), SBP= systolic BP, SNP = single nucleotide polymorphism.
† Difference of BP mean values between wildtype (reference value, AA) and variant (AG+GG) carriers.
‡ Unadjusted P values were obtained using unpaired Student t test to detect signiﬁcant BP differences between wildtype (AA) and variant (AG+GG) carriers.
x Adjusted P values obtained using binomial logistic regression analyses correcting for sex, age, body mass index (kg/m2), smoking, diabetes, and antihypertensive poly-medication.
∗
P< .05.
∗∗
P< .01.
Xu et al. Medicine (2017) 96:30 Medicineabundant rs4680 alleles compared with wildtype carriers
(P= .0017) (Fig. 2B). The interaction between rs4680 genotypes
and sex was also strongly associated with SBP in individuals
treated with CCBs (P= .048). However, this result should be
interpreted with caution since the observed statistical power was
relatively low (Table 5). In addition, subgroups stratiﬁed by sex
did not show signiﬁcant differences in BP in participants taking
CCBs between wildtype and rs4680 carriers in either males or
females (P> .05) (Table 6). Investigations in the very small
subgroup of individuals≥70 years treated with CCBs revealed a
beneﬁcial association of SNP rs4680 with SBP and DBP in elderly
male individuals [SBP/DBP: 150.62/80.04 (AA, n=31) versus
130.45/71.18 mmHg (AG or GG, n=13), padj=3.26x10
-5 (SBP)
and 6.07x10-4(DBP)] compared to elderly women [138.93/73
mmHg (AA, n=7) versus 134.81/74.87 mmHg (AG or GG, n=
26), padj=not signiﬁcant for SBP and DBP].
3.5. The combined occurrence of genetic variants in
COMT shows an additive effect on the treatment
outcome with CCBs
Interestingly, a higher COMT score, as constructed based on
the individual abundance of the 3 COMT variants rs4680,Figure 2. The association ofCOMT variant rs4680 with blood pressure under the tr
B) Elderly individuals treated with CCBs and carrying the G allele of rs4680 show
strongly pronounced in homozygous rs4680 variant carriers. (C) DBP was lower
carriers.
∗
P< .05,
∗∗
P< .01,
∗∗∗
P< .005. P values were obtained using the unpair
diastolic blood pressure, SBP = systolic blood pressure.
6rs737865, and rs165599, was signiﬁcantly associated with
lower SBP in participants taking CCBs (P= .019). This strong
association was maintained when adjusting for sex and age
(P= .018) (Table 7). Furthermore, after correcting for age and
sex, participants treated with CCBs and reaching scores that
belong to the highest quartile of the COMT score showed a
signiﬁcantly lower SBP than individuals belonging to the lowest
COMT score quartile (P= .001) (Table 7).4. Discussion
In this large population-based study, we showed that genetic
variants affecting estrogen metabolism are signiﬁcantly associat-
ed with a modulated effect of antihypertensives especially in
elderly individuals. To our knowledge, this is the ﬁrst study that
identiﬁes COMT as a clinically signiﬁcant susceptibility gene for
the therapeutic effect of CCBs.
Previous studies obtained either inconsistent results regarding
the relation of here investigated estrogen-related SNPs with the
prevalence of hypertension or BP regulation.[3,4,13,29,30] The
association of estrogen-related polymorphisms with hyperten-
sion has only been tested for the SNPs rs4680 (COMT) and
rs10046 (CYP19A1). Importantly, none of the mentioned SNPseatment of calcium-channel blockers (CCBs) in elderly individuals (age≥ 70). (A,
ed signiﬁcantly lower SBP levels than wildtype carriers. This observation was
in elderly rs4680 carriers treated with CCBs compared with elderly wildtype
ed Student t test (2-sided) or general linear model (univariate) analysis. DBP =
Table 7
Associations of the genetic COMT score with blood pressure in patients treated with CCBs.
Linear regression analyses
Outcome: SBP Outcome: DBP
Subjects Model Predictor Beta P Predictor Beta P
CCBs Model 1† (N=168) COMT 0.181 .019∗ COMT 0.075 .336
Model 2‡ (N=168) COMT 0.179 .018∗ COMT 0.073 .327
Sex (F=0) 0.121 .108 Sex (F=0) 0.063 .402
Age 0.224 .003
∗∗
Age 0.303 .000∗∗
Model 3x (N=123) qtCOMT 0.283 .001∗∗ qtCOMT 0.154 .075
Sex (F=0) 0.135 .120 Sex (F=0) 0.096 .268
Age 0.170 .052 Age 0.304 .001∗∗
P values< .05 were considered as signiﬁcant and shown in bold.
Beta= standardized beta coefﬁciency, BP=blood pressure, CCBs=calcium-channel blockers, COMT = COMT score, DBP=diastolic BP, F = female, N=number of subjects, qtCOMT = the lowest and the
highest COMT score quartiles, SBP= systolic BP.
† Linear regression models investigating the impact of the genetic COMT score on BP.
‡Multiple-linear regression models adjusted for the COMT score, sex (F=0), and age.
xMultiple-linear regression models adjusted for the lowest and the highest COMT score quartiles, sex (F=0), and age.
∗
P< .05.
∗∗
P< .01.
Xu et al. Medicine (2017) 96:30 www.md-journal.comhave been investigated in relation to the therapeutic effect of
distinct antihypertensive drug groups.
We demonstrate that the coding variant rs4680 (COMT) is
signiﬁcantly associated with lower SBP levels especially in elderly
individuals taking CCBs. Rs4680 is commonly occurring with a
minor allele frequency of 49.80% in our cohort (50% in white
populations[31,32]), which allows powerful pharmacogenetic
investigations even in groups comprising smaller samples sizes.
Previous studies demonstrated that rs4680 was signiﬁcantly
associated with increased COMT activity, lower BP levels, and
lower prevalence of hypertension.[19–21,30,33,34] Interestingly, weFigure 3. Hypothesized functional pathway causing the age-related impact of COM
protein levels, and enzyme activity are inﬂuenced by age and genetic variants. The p
COMT activity. The Val (G) allele is associated with signiﬁcantly higher COMT activit
different genotypes of the coding SNP rs4680. Since COMT catalyzes the breakd
COMT expression and activity causes a decrease of circulating catecholamine an
blood pressure levels as well. The estrogen-dependent regulation of COMT expres
the observation that speciﬁcally elderly male variant carriers proﬁted from a BP low
small sample and is therefore shown with a dashed arrow. BP = blood pressure
7did not per se observe a general effect of this variant on BP levels
but rather in association with distinct antihypertensive treatment
and after stratiﬁcation according to age. This observation may be
a result of a changed COMT-dependent metabolism of catechol-
amines and estrogens. Decreased levels of circulating catechol-
amines induce lower BP levels and cardiac output[35–37] (Fig. 3).
The age-dependent effect of rs4680 may be a result of
signiﬁcantly elevated COMT mRNA expression and protein
activity especially observed in higher age,[34,38] consecutively
leading to a higher metabolism of norepinephrine to normeta-
nephrine, which ultimately results in the beneﬁcial effect on BPT SNP rs4680 on blood pressure regulation. COMTmRNA expression, COMT
olymorphism rs4680 in COMT is associated with major individual differences in
y. Age is associated with increased COMT expression and, thus, activity across
own of catecholamines into methylated metabolites with lower activity, higher
d blood pressure levels. Furthermore, ﬂuid volume and vessel stiffness impact
sion induces a sexually dimorphic effect of rs4680 on COMT activity, leading to
ering effect of CCBs. However, this observed association was made in a very
, SNP = single nucleotide polymorphism.
[39] [12] Fontana V, Luizon MR, Sandrim VC. An update on the pharmaco-
Xu et al. Medicine (2017) 96:30 Medicineseen in the elderly (Fig. 3). These observations underline
the importance of age-speciﬁc adjustments of antihypertensive
treatment.
Our adjusted analyses suggest a sexually dimorphic beneﬁcial
effect of rs4680 on SBP regulation in individuals treated with
CCBs. According to the results, speciﬁcally elderly male carriers
of rs4680 showed lower SBP under CCBs. This observation
may be a result of estrogen-dependent higher COMT activity
and subsequent lower circulating catecholamine levels in
males[14,40,41] (Fig. 3). This observation was, however, not
conﬁrmed in whole cohort based subgroup analyses stratifying
by sex, putatively because of a too small sample size in our study.
While association of the COMT variants rs737865 and
rs165599 with the therapy effect of diuretics and CCBs on BP did
not remain signiﬁcant after Bonferroni correction, the general
importance of COMT variants for antihypertensive therapy is
further supported by an additive effect of COMT SNPs on BP
under CCBs that we observed in our study.
Other investigated SNPs (i.e., the UGT1A SNPs rs2070959
and rs887829, or rs10046 of CYP19A1) were not associated
with changes in BP levels under antihypertensives.
Future studies should elucidate, why an age-dependent effect is
speciﬁcally observed for CCBs in relation to a polymorphic
expression of COMT. Those investigations should take even
larger numbers of individuals into consideration speciﬁcally
treated with the therapeutics in focus. Furthermore, future studies
should also take applied drug dosages, estrogen replacement
therapy, and the compliance to the treatment into consideration,
which we were not able to correct for in our analyses.
In conclusion, we detected age-related differences in the
therapeutic effect of CCBs, in association with a commonly
occurring genetic variant in the COMT gene. Our results propose
a relevant role of estrogen and catecholamines in the age-speciﬁc
pathogenesis of hypertension and underline the need for
individualized therapy approaches taking age into account.
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